Immunicum

36 articles with Immunicum

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
• 

  A Look at ESMO as Companies Share Oncology Updates

  9/17/2020

  The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.

• Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

  7/27/2020

  Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust

• 

  BioSpace Movers & Shakers, April 3

  4/3/2020

  Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.

• Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project

  8/1/2019

  Immunic, Inc. announced that the German Federal Ministry of Education and Research has awarded its subsidiary, Immunic AG, a grant in the amount of up to EUR 653,535 in support of the InnoMuNiCH project.

• 

  BioSpace Global Roundup, June 13

  6/13/2019

  Companies from across the globe share business and pipeline updates.

• Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019

  4/25/2019

  At the Annual General Meeting of Immunicum AB (publ), reg. no 556629-1786, on April 25, 2019 the AGM adopted, inter alia, the following resolutions.

• Immunicum AB (publ) Interim Report January - March 2019

  4/25/2019

  Preparations for Upcoming Clinical Data in the MERECA and GIST Studies and First Patient Treated in the ILIAD Study

• Immunicum AB (publ) Publishes the Annual Report for 2018

  4/4/2019

  Immunicum AB, announced that its Annual Report for 2018 is now available on the company's website, www.immunicum.com.

• Notice of Annual General Meeting in Immunicum AB (publ)

  3/26/2019

  The shareholders of Immunicum AB, reg. no 556629-1786, are hereby invited to the Annual General Meeting on Thursday, 25 April 2019, at 10:30, at Sturegatan 15's premises, at Sturegatan 15, SE-161 14 36 Stockholm.

• Immunicum AB (publ) Announces Upcoming Conferences in March and April

  3/23/2019

  Immunicum AB announced that members of the management team will attend and present at upcoming conferences in March and April.

• Immunicum AB (publ) Year-End Report 2018

  2/15/2019

  Immunicum announced a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate ilixadencel in combination with Avelumab in multi-in­dication phase Ib/II study ILIAD.

• Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue

  1/31/2019

  Immunicum AB has, as previously announced, implemented a share issue with preferential rights for the Company's existing shareholders.

• Changes to the Nomination Committee for Immunicum AB (publ)

  1/30/2019

  Immunicum AB announced the composition of the Nomination Committee on 19 October 2018.

• Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Directed Issue

  12/28/2018

  Immunicum AB has, as previously announced, implemented a directed issue to a number of institutional and private investors. The newly implemented share issue has entailed a change in number of shares and votes in the Company.

• Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study

  11/16/2018

  Immunicum AB announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial.

• Immunicum AB (publ) Interim Report July - September 2018

  11/9/2018

  Positive preclinical results presented at ESMO

• Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018

  11/8/2018

  The Extraordinary General Meeting (the "EGM") of Immunicum AB (publ), reg. no 556629-1786, was held today.

• Immunicum AB: Invitation to Investor Events in Gothenburg and Stockholm

  10/25/2018

  Immunicum AB (publ; IMMU.ST) announced today that the Company will host two investor events in October. At both events, Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session.   

• Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018

  10/23/2018

  -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model --